Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EBIT (2018 - 2025)

Historic EBIT for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$19.5 million.

  • Whitehawk Therapeutics' EBIT fell 4572.43% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.5 million, marking a year-over-year decrease of 6378.3%. This contributed to the annual value of -$67.5 million for FY2024, which is 622.11% up from last year.
  • According to the latest figures from Q3 2025, Whitehawk Therapeutics' EBIT is -$19.5 million, which was down 4572.43% from -$54.7 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' EBIT peaked at -$3.9 million during Q2 2021, and registered a low of -$87.3 million during Q3 2021.
  • Moreover, its 5-year median value for EBIT was -$16.8 million (2023), whereas its average is -$21.2 million.
  • In the last 5 years, Whitehawk Therapeutics' EBIT plummeted by 317867.07% in 2021 and then surged by 8277.88% in 2022.
  • Quarter analysis of 5 years shows Whitehawk Therapeutics' EBIT stood at -$15.9 million in 2021, then rose by 2.97% to -$15.5 million in 2022, then dropped by 14.49% to -$17.7 million in 2023, then decreased by 6.97% to -$18.9 million in 2024, then decreased by 3.15% to -$19.5 million in 2025.
  • Its EBIT stands at -$19.5 million for Q3 2025, versus -$54.7 million for Q2 2025 and -$15.2 million for Q1 2025.